Investors

Corporate Overview

Monet pharmaceuticals is a privately held pharmaceutical company with research facilities at George Mason University in Manassas, Virginia, USA.  Monet has invented a novel drug discovery technology known as protein painting.  Protein painting has the potential to transform the drug development process by facilitating a simpler, faster and more effective path to the identification of druggable protein targets sites for drug discovery.

Monet is poised to identify novel targets across a broad range of diseases.  

Monet is leveraging its proprietary technique to develop its own pipeline of drug candidates.   Monet expects to initiate clinical trials with its first lead compound by the second half of 2021.

Monet will forge partnerships and collaborations with bio-pharmaceutical companies seeking to leverage its novel drug discovery technology.   In addition to securing access to Monet’s technology, partnering companies will have access to the Monet’s team of experts and know-how to collaborate on the development of independent leads.